BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28178155)

  • 1. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.
    Abe T; Sasaki A; Ueda T; Miyakawa Y; Ochiai H
    Medicine (Baltimore); 2017 Feb; 96(6):e6056. PubMed ID: 28178155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab in secondary atypical haemolytic uraemic syndrome.
    Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
    Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report.
    Nakamura M; Abe T; Ochiai H
    Am J Case Rep; 2022 Jun; 23():e936116. PubMed ID: 35671252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
    Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
    Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
    Kourouklaris A; Ioannou K; Athanasiou I; Panagidou A; Demetriou K; Zavros M
    J Med Case Rep; 2014 Sep; 8():307. PubMed ID: 25219386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].
    Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F
    G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
    J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
    Fujita Y; Terashita M; Yazawa M; Yamasaki Y; Imamura T; Kibayashi J; Sawai T; Hidaka Y; Ohtani K; Inoue N; Shibagaki Y
    Intern Med; 2020; 59(1):93-99. PubMed ID: 31902910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
    Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab treatment of thrombotic microangiopathy in a patient with ulcerative colitis.
    Øzbay LA
    Clin J Gastroenterol; 2020 Jun; 13(3):344-348. PubMed ID: 31612381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report.
    Omura T; Watanabe E; Otsuka Y; Yoshida Y; Kato H; Nangaku M; Miyata T; Oda S
    Medicine (Baltimore); 2016 Jul; 95(27):e4104. PubMed ID: 27399110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
    Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
    Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.
    Bjørkto MH; Barratt-Due A; Nordøy I; Dörje C; Galteland E; Lind A; Hilli A; Aukrust P; Mjøen G
    BMC Infect Dis; 2021 Feb; 21(1):137. PubMed ID: 33526010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
    Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
    J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.